All News

Real world interchangeabilty study compared rituximab to biosimilar ( CT-P10) in 128 Rheum pts (CT-P10= 64; RTX= 64), with 41% of pts switched from RTX to CT-P10. Both Rx had Comparable Gr 2 infuxion Rxs, infection #s & hypogammaglobulinemia (p > 0.05) https://t.co/RNxt7Xn7MJ https://t.co/u3yJNQQIMC

Links:

Dr. John Cush RheumNow ( View Tweet)
Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis A retrospective study of cancer patients who developed ICI-IA shows that biologic DMARDs were more effective than csDMARDs in rapid control of arthritis. https://t.co/EQjSgav0by https://t.co/CZ0IqR3UXM

Links:

Dr. John Cush RheumNow ( View Tweet)
RA Patients on Biologics and tsDMARDs are still High Risk A new Swedish ARTIS registry study of key safety outcomes in RA patients receiving either targeted synthetic or b/ts DMARDs, including JAKi, has been updated and affirms previously held risks. https://t.co/mqfP4deGJv https://t.co/m43GSRlrct

Links:

Dr. John Cush RheumNow ( View Tweet)
Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis A retrospective study of cancer patients who developed ICI-IA shows that biologic DMARDs were more effective than csDMARDs in rapid control of arthritis. https://t.co/O5bMpwwM8Z https://t.co/H27RSA3oMt

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us April 18 for: Private Practice & Academia In this session, our panelists will address the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?". https://t.co/BrWG57mRRG https://t.co/A0pzEvJ3cu

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective of 28,360 #PsA pts saw more comorbidities by race - AAs had signif. more HTN (59% vs 52%), DM (31% vs 23%), obesity (47% vs 30%) & gout (12% vs 8%); but whites more cancer (20% vs 16%), anxiety (28% vs 23%), OP(14% vs 12%), more biologic use https://t.co/YwGjVowO3G https://t.co/3BUXFX11rh

Links:

Dr. John Cush RheumNow ( View Tweet)
computer screen safety

RA Patients on Biologics and tsDMARDs are still High Risk

d Jack Cush, MD

A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.

Read Article
price%20dollar%20pill.jpg

Industry Payments to Rheumatologists Dropped During COVID

d MedPage Today

Having their clinics shut down and patients staying away during the COVID-19 pandemic was bad enough for physicians' finances, but now a new study finds that, at least for rheumatologists, payments from industry dried up as well.

Read Article
Dutch Biologic Monitor surveys of RA, PsA, axSpA pts on etanercept or adalimumab, looked at adverse drug reactions. Among 748 consecutive pts on biologics, women had more ADRs (55%) than men (38%). nature ofreported ADRs differed betw sexes (p = 0.02). https://t.co/fGRgX4IJLR https://t.co/FJE7BrKPfQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Pooled data from 3 RCTs in PsA compared tofacitinib vs. adalimumab in 816 pts. Baseline, women had higher TJC, enthesitis, HAQ-DI, FACIT-F (Males more dactylitis). Sexes had equal ACR20/50/70, PASI75, ∆HAQ-DI, & persistence, but females less achieved MDA https://t.co/LICWVjI2kH https://t.co/8RipVIEWyJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Inflammasome inhibitors in development: - RRx-001 in cancer, ALS, parkinsons - OLT1177 in OA knee, gout, Schnitzlers - DFV890 in CAPs, knee OA - IZD174/334 in CAPS - ZYIL1 CAPS https://t.co/7E2jdx9TPA https://t.co/R5Uu5mjIym

Links:

Dr. John Cush RheumNow ( View Tweet)
The Origin Story: Women in Rheumatology--The XX Factor When asked to run a campaign to highlight the achievements and challenges of women in rheumatology, I was ecstatic because we have has so many heroines who have contributed to our field. https://t.co/ucQIPjQ8Tu https://t.co/g81EtAwYYL

Links:

Dr. John Cush RheumNow ( View Tweet)
hospital-834152_640.jpg

Steroid-Sparing Rituximab in Polymyalgia Rheumatica

d Jack Cush, MD

BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year. 

Read Article
guidelines.jpg (keep)

British Society of Rheumatology Plans Revision of Systemic Sclerosis Guideline

d Jack Cush, MD

British Society for Rheumatology (BSR) last published its guideline for systemic sclerosis (SSc) in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.

Read Article
Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor. Sign up to attend our Tuesday Night Rheumatology series. @uptoTate @KDAO2011 https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN

Links:

Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for Tuesday Night Rheumatology. Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations. https://t.co/OlP0pupkMV https://t.co/pZQMASafcG

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/ZxJylP7IUk https://t.co/Kmx1dkHycM

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center study of 320 Difficult to Rx RA (D2TRA) pts, found 76 EULAR-D2TRA pts (24%). D2TRA more likely to be lower socio-economic, RF+, have ILD, higher DAS28-CRP and were more likely to respond to rituximab and JAK inhibitors https://t.co/aEvP6WDvQu https://t.co/FQJvo81FbM

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Night Splinting for Carpal Tunnel (3.24.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com.  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

Read Article
The Biosimilar "Buy In" Dr. Rachel Tate, @uptotate , shared insights into these key discussions during RheumNow Live. https://t.co/dD3uZCNQEo https://t.co/MuN91Oqbvo

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.